Small animal imaging for accelerating drug development, and comparison to other techniques

Trends on the Role of PET in Drug Development

Volumn , Issue , 2012, Pages 219-240

  Alstrup, Aage Kristian Olsen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84986626909     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789814317740_0009     Document Type: Chapter

References (50)

1. Aboagye EO. Positron emission tomography imaging of small animals in anticancer drug development. Mol Imag Biol 2005; 7: 53-58.
2. Alstrup AKO, Winterdahl M. Imaging techniques in large animals. Scand J Lab Anim Sci 2009; 36: 1-12.
3. Avril N, Propper D. Functional PET imaging in cancer drug development. Future Oncol 2007; 3: 215-228.
4. /-[18F] Fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63: 3791-3798.
5. Beckmann N, Kneuer R, et al. In vivo mouse imaging and spectroscopy in drug discovery. NMR Biomed 2007; 20: 154-185.
6. Blasberg RG. In vivo molecular-genetic imaging: multi-modality nuclear and optical combinations. Nucl Med Biol 2003; 30: 879-888.
7. Boss DS, Olmos RV, et al. Application of PET/CT in the development of novel anticancer drugs. Oncolog 2008; 13: 25-38.
8. Cherry SR. Fundamentals of positron emission tomography and application in preclinical drug development. J Clinic Pharmacol 2001; 41: 482-491.
9. Cherry SR. In vivo molecular and genomic imaging: new challenges for imaging physics. Phys Med Biol 2004; 49: R13-R48.
10. Collingridge DR, Glaser M, et al. In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitted radioisotope. Br J Cancer 2003; 89: 1327-1333.
11. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 2004; 3: 417-429.
12. DiMasi JA. The value of improving the productivity of the drug development process: Faster times and better decisions. Pharmacoeconomics 2002;20:1-10.
13. Eckelman WC. The use of PET and knockout mice in the drug discovery process. Drug Discov Today 2003; 8: 404-410.
14. Farde L, Andrée B, et al. PET-determination of robalzotan (NAD-299) induced 5-HT(1A) receptor occupancy in the monkey brain. Neuropsychopharmacology 2000; 22: 422-429.
15. Feinendegen LE, Pollycove M. Biologic responses to low doses of ionizing radiation: detriments versus hormesis. J Nucl Med 2001; 42: 17N-27N.
16. Funk T, Sun M, et al. Radiation dose estimate in small animal SPECT and PET. Med Phys 2004; 31: 2680-2686.
17. Gross S, Piwnica-Worms D. Molecular imaging strategies for drug discovery and development. Current Opinion Biol 2006; 10: 334-342.
18. Herholz K, Carter SF, et al. Positron emission tomography imaging in dementia. Br J Radiol 2007; 80: S160-S167.
19. 15O] water be used to evaluate drugs? J Clin Pharmacol 2001; Suppl.: 11S-20S.
20. Hsu AR, Cai W, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 2007; 48: 445-454.
21. Klunk WE, Loprest BJ, et al. Binding of the positron emission tomography tracer Pittsburg compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci 2005; 25: 10598-10606.
22. Knowles J, Gromo G. A guide to drug discovery: target selection in drug discovery. Nat Rev Drug Discov 2003; 2: 63-69.
23. Koo V, Hamilton PW, et al. Non-invasive in vivo imaging in small animal research. Cel Oncol2006; 28: 127-139.
24. Kung M, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol 2005; 32: 673-678.
25. 18F-paclitaxel in nonhuman primates. J Nucl Med 2003; 44: 1330-1339.
26. Lee C-M, Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006; 27: 310-316.
27. Lesko LJ, Rowland M, et al. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res 2000; 17: 1335-1344.
28. Madrigal JL, Garcia-Bueno B, et al. Stress-induced oxidative changes in brain. CNS Neurol Disord — Dr 2006; 5: 561-568.
29. 18F] FDG PET studies using a standard arterial input function. Eur J Nucl Med Mol Imag 2006; 33: 948-954.
30. Momosaki S, Hatano K, et al. Rat-PET study without anesthesia: anesthetics modify the dopamine D1 receptor binding in rat brain. Synapse 2004; 54: 207-213.
31. Murphy PS, Bergström M. Radiopharmaceuticals for oncology drug development: a pharmaceutical industry perspective. Curr Pharm Dis 2009; 15: 957-965.
32. Myers R. The biological application of small animal PET imaging. Nucl Med Biol 2001; 28: 585-593.
33. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000; 57: 39-43.
34. Olsen AIK, Zeidler D, et al. Imaging techniques: CT, MRI, and PET scanning. In: Swine in the Laboratory. Surgery, Anesthesia, Imaging, and Experimental Techniques (ed.) MM Swindle: Boca Raton: CRC Press, 2007, pp. 387-396.
35. Oyama N, Ponde DE, et al. Monitoring of therapy in androgen-dependent prostata tumor by measuring tumor proliferation. J Nucl Med 2004; 45: 519-525.
36. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003; 3: 90-105.
37. Pedersen K, Simonsen M, et al. Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: modulation by MAO-inhibition. Neuroimage 2007; 35: 38-46.
38. Preziosi P. Science, pharmacoeconomics and ethics in drug R & D: a sustainable future scenario? Nat Rev Drug Discov 2004; 3: 521-526.
39. Price P. The role of PET scanning in determining pharmacoselective doses in oncology drug development. Ernst Schering Res Found Workshop 2007; 59:185-193.
40. Riemann B, Schäfers KP, et al. Small animal PET in preclinical studies: opportunities and challenges. QJ Nucl Med Mol Imag 2008; 52: 215-221.
41. Spaepen K, Stroobants S, et al. [(18)]FDG PET monitoring of tumor response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumor cell fraction? Eur J Nucl Med Mol Imag 2003; 30: 682-688.
42. Thorwarth D, Eschmann SM, et al. A kinetic model for dynamic [18F]-Fmizo PET data to analyse tumour hypoxia. Phys Med Biol 2005; 50: 2209-2224.
43. 18F] FPWAY in blood and brain of the rat with and without isoflurane anaesthesia. Eur J Nucl Med Mol Imag 2007; 34: 259-266.
44. Wang J, Mauer L. Positron Emission Tomography: applications in drug discovery and drug development. Curr Top Med Chem 2005; 5: 1053-1075.
45. Wehrl HF, Judenhofer MS, et al. Pre-clinical PET/MR: technological advances and new perspectives in biomidical research. Eur J Nucl Mol Imag 2009; 36: S56-S68.
46. Woodruff-Pak DS. Animal models of Alzheimers's disease: therapeutic implications. J Alzheimers Dis 2008; 15: 507-521.
47. Yagle KJ, Eary JF, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005; 46: 658-666.
48. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs: will they model the next 100? Nat Rev Drug Discov 2003; 2: 38-51.
49. Zanzonico P, O'Donoghue J, et al. Iodine-124-labaled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imag 2004; 31: 117-128.
50. Zhang Y, Saylor M, et al. Longitudinally quantitative 2-deoxy-2-[18F] fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model. Mol Imag Biol 2006; 8: 300-308.